Dr. Yardley on the Results of the APT and APHINITY Trials for HER2+ Breast Cancer

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the results of the APT and APHINITY trials for patients with HER2-positive breast cancer.

The durable response from the APT trial at 5 and 7 years has shown that patients have continued to see benefits, explains Yardley. According to Yardley, this is changing the dynamic of HER2-positive breast cancer.

Additionally, the magnitude of benefit from the addition of trastuzumab (Herceptin) in the APHINITY trial has been tremendous and continues to reduce a patient’s risk for recurrence, states Yardley.